RECRUITING

Immune Cells During Disuse and Recovery

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is an interventional study enrolling healthy individuals aged 18-35 and 60-85 to understand the recovery of muscle health following a period of inactivity. The enrollment goal is 45 participants. The study will occur over the course of 1-2 months where participants will undergo testing before and after a 2-week limb immobilization period.

Official Title

Muscle Immune Cells During Disuse and Recovery in Aging and Metabolic Disease

Quick Facts

Study Start:2022-05-15

Study Completion:2028-04-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04416191

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 85 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Age between 18-35 and 60-85 yrs 2. Ability to sign informed consent 3. Free-living, prior to admission	* History of cardiovascular disease (e.g., CHF, CAD, right-to-left shunt) * History of endocrine or metabolic disease such as hypo/hyperthyroidism and diabetes * History of kidney disease or failure * Vascular disease * Risk of DVT including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb\>18 g/dL) or thrombocytosis (platelets\>400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocystinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombine III * Use of anticoagulant therapy (e.g., Coumadin, heparin) * Elevated systolic pressure \>150 or a diastolic blood pressure \> 100 * Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators) * Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma * Currently on a weight-loss diet * Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids are permitted) * Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement is permitted) * History of stroke with motor disability * A recent history (\<12 months) of GI bleed * History of liver disease * History of respiratory disease (acute upper respiratory infection, history of chronic lung disease) * Pregnancy as determined by a pregnancy test * Any staff members who report directly to an investigator or who report to someone who reports directly to an investigator. * Any other condition or event considered exclusionary by the PI and faculty physician

Inclusion Criteria

Exclusion Criteria

1. Age between 18-35 and 60-85 yrs
2. Ability to sign informed consent
3. Free-living, prior to admission

* History of cardiovascular disease (e.g., CHF, CAD, right-to-left shunt)
* History of endocrine or metabolic disease such as hypo/hyperthyroidism and diabetes
* History of kidney disease or failure
* Vascular disease
* Risk of DVT including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb\>18 g/dL) or thrombocytosis (platelets\>400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocystinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombine III
* Use of anticoagulant therapy (e.g., Coumadin, heparin)
* Elevated systolic pressure \>150 or a diastolic blood pressure \> 100
* Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)
* Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma
* Currently on a weight-loss diet
* Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids are permitted)
* Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement is permitted)
* History of stroke with motor disability
* A recent history (\<12 months) of GI bleed
* History of liver disease
* History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)
* Pregnancy as determined by a pregnancy test
* Any staff members who report directly to an investigator or who report to someone who reports directly to an investigator.
* Any other condition or event considered exclusionary by the PI and faculty physician

Contacts and Locations

Study Contact

Micah Drummond, PhD

CONTACT

801-213-2737

micah.drummond@hsc.utah.edu

Principal Investigator

Micah Drummond, PhD

PRINCIPAL_INVESTIGATOR

University of Utah

Study Locations (Sites)

The University of Utah

Salt Lake City, Utah, 84112

United States

Collaborators and Investigators

Sponsor: University of Utah

Micah Drummond, PhD, PRINCIPAL_INVESTIGATOR, University of Utah

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-15

Study Completion Date2028-04-30

Study Record Updates

Study Start Date2022-05-15

Study Completion Date2028-04-30

Terms related to this study

Additional Relevant MeSH Terms

Muscle Disuse